Drug Trial Radar · NCT05272813
A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL
Last checked: Nov 19, 2026Latest source record: Jul 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
13
Actual
Start
Apr 28, 2022
Primary completion
Nov 28, 2023
Study completion Nov 28, 2023
Sponsor
- Lead sponsor
- Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 9, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I/II, single arm, multi-center, open-label clinical trial of MS-553 in patients with CLL/SLL whose disease relapsed after or was refractory to at lease 1 prior therapy (chemotherapy and/or targeted drug therapy, which must include BTK inhibitor therapy) and who are indicated for treatment per IWCLL2018.
Conditions
- Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
Interventions
MS-553Drug
MS-553
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose limiting toxicitiesTime frame: 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, Xicheng District, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.